Skip to main content
Premium Trial:

Request an Annual Quote

NYU, Rosetta Genomics to Co-develop miRNA-based Lung Cancer Test

NEW YORK (GenomeWeb News) - Rosetta Genomics and New York University Medical Center said today that they plan to co-develop diagnostic tests for lung and mesothelioma cancers.
 
The early-detection tests will use Rosetta's technology for extracting microRNA from blood.
 
The tests will identify patients at risk of lung cancer due to smoking as well as those who have been exposed to asbestos fibers.
 
"MicroRNAs have been shown to hold great potential as effective biomarkers for various cancers," said Harvey Pass, chief of NYU Medical Center's Thoracic Surgery and Thoracic Oncology divisions, in a statement. 
 
Financial terms of the agreement were not released.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.